Trials / Completed
CompletedNCT01979016
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | |
| DRUG | Placebo | Matching placebo |
| OTHER | Background treatment | Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8). |
Timeline
- Start date
- 2013-12-31
- Primary completion
- 2014-12-31
- Completion
- 2015-01-31
- First posted
- 2013-11-08
- Last updated
- 2020-03-18
- Results posted
- 2020-03-18
Locations
4 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT01979016. Inclusion in this directory is not an endorsement.